Prolia (Denosumab) Cost in Missouri: Prices, Insurance, and Savings for 2026

What Prolia (Denosumab) Costs at Missouri Pharmacies in 2026

The average cash-pay price for a single 60 mg prefilled syringe of Prolia at Missouri retail pharmacies sits around $1 to 500 in 2026. That figure tracks closely with Amgen's national wholesale acquisition cost (WAC) and has remained stable since the drug's original FDA approval in 2010 for postmenopausal women at high fracture risk [1]. Because Prolia is dosed as a subcutaneous injection every six months, the annual branded cost for an uninsured patient amounts to roughly $3,000.

Pricing can vary by pharmacy location within the state. Specialty pharmacies affiliated with health systems like BJC HealthCare in St. Louis or University of Missouri Health Care in Columbia sometimes negotiate contracted rates that differ from standalone retail outlets. Patients should request a direct price quote rather than relying on published averages. The drug is classified as a "buy-and-bill" medication when administered in a physician's office, meaning the provider purchases it and bills the insurer, which can shift the cost burden depending on your plan's medical (rather than pharmacy) benefit structure [2].

One factor that keeps Prolia's price elevated: no FDA-approved biosimilar for the 60 mg osteoporosis dose has launched in the U.S. as of mid-2026. Sandoz and other manufacturers have biosimilar candidates in regulatory review, but until one reaches market, Amgen faces limited price competition on the branded product [3].

Missouri Medicaid and Prolia: A Coverage Gap for Osteoporosis

Missouri Medicaid (MO HealthNet) does not cover Prolia for osteoporosis treatment. Coverage is restricted to type 2 diabetes indications only. This creates a significant access barrier for the roughly 500,000 Missourians enrolled in Medicaid who may have osteoporosis or osteopenia requiring pharmacologic intervention [4].

The Endocrine Society's 2020 clinical practice guideline recommends denosumab as a first-line option for postmenopausal osteoporosis, particularly in patients with renal impairment where bisphosphonates carry higher risk [5]. Dr. Michael McClung, founding director of the Oregon Osteoporosis Center, noted in a 2020 review that "denosumab is the preferred agent for patients with chronic kidney disease stages 4 and 5, where bisphosphonates are contraindicated or poorly studied" [5]. For Missouri Medicaid patients who fall into this category, the coverage exclusion forces difficult choices.

Options for Medicaid-enrolled patients include appealing through the MO HealthNet prior authorization process (citing medical necessity and bisphosphonate contraindication), applying for Amgen's Safety Net Foundation program, or exploring compounded denosumab through a licensed 503A pharmacy. Oral bisphosphonates like alendronate remain covered under Missouri Medicaid and cost as little as $4 per month at generic pricing, but they are not always clinically appropriate.

Which Missouri Insurance Plans Cover Prolia?

Most commercial insurance plans available in Missouri, including those sold on the federal marketplace (healthcare.gov) and employer-sponsored plans, cover Prolia with prior authorization. The prior authorization typically requires documentation that the patient has a T-score of -2.5 or lower on DXA scan, or a history of fragility fracture, or has failed or is intolerant to oral bisphosphonate therapy [6].

Blue Cross Blue Shield of Kansas City (Blue KC), one of the largest insurers in the Missouri market, lists Prolia on its specialty tier formulary. Anthem (operating as Healthy Alliance in parts of Missouri), Cigna, UnitedHealthcare, and Aetna all maintain similar coverage policies with step-therapy requirements. Step therapy usually means the patient must trial and fail (or document intolerance to) at least one oral bisphosphonate such as alendronate or risedronate before the plan approves Prolia [7].

Medicare Part B covers Prolia when administered in a physician's office under the medical benefit. The patient pays 20% coinsurance after meeting the Part B deductible ($257 in 2026), which amounts to roughly $300 per injection out of pocket. Medicare Advantage plans may have different cost-sharing structures, so patients should verify with their specific plan.

A key detail often missed: if your plan covers Prolia under the medical benefit (Part B or commercial medical), the cost appears as a medical claim, not a pharmacy claim. This means pharmacy discount cards and GoodRx-style coupons do not apply. Patients need to confirm which benefit covers the drug before pursuing discount strategies.

How the Amgen Savings Card Works in Missouri

Amgen operates two patient assistance pathways for Prolia, and both are available to Missouri residents. The first is the Prolia copay card for commercially insured patients. Eligible patients can reduce their out-of-pocket cost to as little as $0 per injection, with Amgen covering up to a set annual maximum (typically $3,000 per year). The card cannot be used with Medicare, Medicaid, TRICARE, or other government-funded insurance [8].

Enrollment is straightforward. Patients register through the Amgen website or receive a card directly from their prescribing physician's office. The card is presented at the point of billing (either at the pharmacy or at the physician's office for buy-and-bill). One restriction: the copay card covers cost-sharing only, not the full drug price. You must have active commercial insurance that covers Prolia for the card to apply.

The second pathway is Amgen's Safety Net Foundation, a separate charitable program for uninsured or underinsured patients. This program can provide Prolia at no cost to patients who meet income eligibility requirements (generally household income at or below 400% of the federal poverty level). Missouri patients on Medicaid who are denied coverage for Prolia's osteoporosis indication may qualify for Safety Net if they have no other coverage for the drug [8].

Compounded Denosumab in Missouri: Legal Status and Availability

Compounded denosumab is available through licensed 503A compounding pharmacies in Missouri. Section 503A of the Federal Food, Drug, and Cosmetic Act permits state-licensed pharmacies to compound medications based on individual patient prescriptions, provided they meet specific conditions: a valid patient-prescriber relationship exists, the compounded product is not a copy of a commercially available drug in terms of strength and dosage form, and the pharmacy does not compound in bulk for distribution [9].

Missouri's Board of Pharmacy regulates 503A pharmacies under state compounding rules that align with federal requirements. The practical effect: a Missouri physician can write a prescription for compounded denosumab, and a 503A pharmacy in the state can fill it. The cost through compounding pharmacies has been reported at dramatically lower price points than the branded product. Some patients report prices near $0 through specific patient programs tied to compounding networks, though typical pricing varies by pharmacy.

There is a clinical consideration. The FREEDOM trial (N=7,868) established the efficacy and safety profile specifically for Amgen's manufactured denosumab 60 mg prefilled syringe, demonstrating a 68% reduction in vertebral fractures over 36 months compared to placebo [10]. Compounded versions have not undergone equivalent large-scale randomized controlled trials. The American Society for Bone and Mineral Research has not issued a position statement on compounded denosumab specifically, but the FDA has broadly cautioned that compounded biologics may differ in potency, sterility, and stability from FDA-approved products [9].

Patients considering compounded denosumab should discuss the risk-benefit calculus with their prescriber and verify the pharmacy's accreditation, inspection history, and quality-control practices.

Telehealth Prescribing of Prolia in Missouri

Missouri permits telehealth prescribing of Prolia. The Missouri Telehealth Act allows licensed physicians to establish a patient-prescriber relationship via synchronous audio-video consultation and to prescribe medications, including injectable biologics like denosumab [11]. This is relevant for patients in rural Missouri counties where endocrinologists and rheumatologists are scarce.

A telehealth visit can cover the clinical evaluation, DXA scan review, fracture risk assessment (FRAX score calculation), and prescribing. The injection itself requires an in-person visit or home health administration, since Prolia is a subcutaneous injection given by a healthcare professional every six months. Some patients are trained to self-inject, though this is off-label relative to Prolia's labeling, which specifies administration by a healthcare professional [1].

For Missouri patients outside the St. Louis and Kansas City metro areas, telehealth expands access to the specialist evaluation needed for Prolia initiation. The prescribing telehealth provider must hold an active Missouri medical license.

Clinical Evidence Supporting Denosumab for Osteoporosis

The FREEDOM trial, published in the New England Journal of Medicine in 2009, remains the foundational efficacy study for denosumab in postmenopausal osteoporosis. In 7,868 women aged 60 to 90, denosumab 60 mg subcutaneously every 6 months reduced the incidence of new vertebral fractures by 68% (relative risk 0.32 to 95% CI 0.26 to 0.41, P<0.001) over 36 months compared to placebo. Hip fracture risk fell by 40%, and nonvertebral fracture risk decreased by 20% [10].

The 10-year FREEDOM Extension study demonstrated sustained fracture reduction and continued bone mineral density gains through a full decade of treatment. Lumbar spine BMD increased by 21.7% and total hip BMD by 9.2% from the original FREEDOM baseline over 10 years of continuous denosumab [12]. Dr. Henry Bone, a lead investigator on the FREEDOM Extension, stated that "the progressive increase in BMD over 10 years without a plateau is unique among osteoporosis therapies" [12].

A critical safety consideration with denosumab is rebound bone loss upon discontinuation. Within 12 months of stopping, patients can lose all gained bone density and face an elevated risk of multiple vertebral fractures. The 2020 AACE/ACE guideline recommends transitioning patients to a bisphosphonate (typically zoledronic acid) if denosumab is discontinued, rather than stopping treatment abruptly [6]. This rebound risk makes the cost question particularly relevant: patients who start Prolia need a plan for sustained access, since stopping abruptly carries real clinical danger.

Cheapest Ways to Get Prolia in Missouri: A Cost Comparison

The path to the lowest out-of-pocket price depends on your insurance status. Here is a breakdown for Missouri patients:

Commercially insured with Prolia coverage: Apply for the Amgen copay card. If approved, out-of-pocket cost can drop to $0 per injection. Without the copay card, expect specialty-tier copays ranging from $100 to $500 per injection depending on your plan's cost-sharing structure.

Medicare Part B enrollees: Prolia administered in a physician's office is covered under Part B. After meeting the $257 annual deductible, expect 20% coinsurance (roughly $300 per injection). A Medigap supplemental plan may cover this coinsurance. The Amgen copay card cannot be used with Medicare. Patients with limited income may qualify for Medicare's Extra Help or the Amgen Safety Net Foundation.

Uninsured Missouri residents: Apply to the Amgen Safety Net Foundation (income-based eligibility). If ineligible for Safety Net, ask about compounded denosumab through a Missouri-licensed 503A pharmacy, where pricing is significantly below branded cost.

Missouri Medicaid enrollees (denied for osteoporosis): File a prior authorization appeal citing medical necessity. If denied, apply to Amgen Safety Net Foundation. Compounded denosumab through a 503A pharmacy is another option.

Regardless of insurance status, always ask your prescriber's office to run a benefits investigation before the first dose. Many specialty pharmacies and physician offices have staff dedicated to verifying coverage and identifying the lowest-cost pathway.

Prolia vs. Oral Bisphosphonates: Cost Context for Missouri Patients

For context on where Prolia's price sits relative to alternatives, generic alendronate (the oral bisphosphonate most commonly prescribed for osteoporosis) costs $4 to $15 per month at Missouri pharmacies. Generic risedronate runs $15 to $30 per month. Zoledronic acid (Reclast), an annual IV bisphosphonate infusion, has a wholesale cost of approximately $1,200 per infusion but is covered by most insurance plans under the medical benefit [13].

The AACE/ACE 2020 guideline positions denosumab alongside bisphosphonates as a first-line option for high-fracture-risk patients and explicitly recommends it over bisphosphonates when renal function is impaired (eGFR <35 mL/min) [6]. In the FREEDOM trial, the number needed to treat (NNT) to prevent one vertebral fracture over 3 years was 21, and the NNT to prevent one hip fracture was 200 [10]. These NNTs are comparable to those reported for zoledronic acid in the HORIZON trial (NNT of 14 for vertebral fracture, 91 for hip fracture over 3 years) [14].

Cost-effectiveness analyses have generally found denosumab cost-effective at a willingness-to-pay threshold of $50,000 per quality-adjusted life year (QALY), particularly in patients aged 70 and older with T-scores of -3.0 or lower [15]. For younger patients with less severe osteopenia, the cost-effectiveness calculus may favor generic bisphosphonates first.